Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.

Onco Targets Ther · 2010 · PMC2939769 · PMID 20856791

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients on the 25-mg dose showed a trend toward increased PFS and ORR, but this was not statistically significant at the time of study completion.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.